O
ONKURE THERAPEUTICS, INC.
NASDAQ: OKUR (OnKure Therapeutics, Inc.)
Last update: 9 hours ago2.33
-0.05 (-2.10%)
| Previous Close | 2.38 |
| Open | 2.48 |
| Volume | 131,406 |
| Avg. Volume (3M) | 163,332 |
| Market Cap | 31,479,230 |
| Price / Book | 0.370 |
| 52 Weeks Range | |
| Earnings Date | 11 Aug 2025 - 15 Aug 2025 |
| Diluted EPS (TTM) | -4.39 |
| Total Debt/Equity (MRQ) | 1.05% |
| Current Ratio (MRQ) | 11.18 |
| Operating Cash Flow (TTM) | -54.49 M |
| Levered Free Cash Flow (TTM) | -25.21 M |
| Return on Assets (TTM) | -61.00% |
| Return on Equity (TTM) | -108.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | OnKure Therapeutics, Inc. | Mixed | - |
AIStockmoo Score
1.2
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -2.0 |
| Average | 1.17 |
|
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.57% |
| % Held by Institutions | 98.08% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Cormorant Asset Management, Lp | 31 Mar 2025 | 1,837,739 |
| Acorn Capital Advisors, Llc | 31 Mar 2025 | 1,439,674 |
| Perceptive Advisors Llc | 31 Mar 2025 | 1,004,439 |
| Samsara Biocapital, Llc | 31 Mar 2025 | 824,155 |
| Vestal Point Capital, Lp | 31 Mar 2025 | 635,000 |
| Deep Track Capital, Lp | 31 Mar 2025 | 523,989 |
| Stepstone Group Lp | 31 Mar 2025 | 491,938 |
| Nea Management Company, Llc | 31 Mar 2025 | 478,548 |
| Highbridge Capital Management Llc | 31 Mar 2025 | 438,797 |
| Affinity Asset Advisors, Llc | 31 Mar 2025 | 394,159 |
| Carlyle Group Inc. | 31 Mar 2025 | 269,895 |
| Ikarian Capital, Llc | 31 Mar 2025 | 253,754 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 06 May 2025 | Announcement | OnKure Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |